You can buy or sell EDIT and other stocks, options, ETFs, and crypto commission-free!
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). Read More The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA. The listed name for EDIT is Editas Medicine, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 9, After Hours